JP2002522508A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002522508A5 JP2002522508A5 JP2000564651A JP2000564651A JP2002522508A5 JP 2002522508 A5 JP2002522508 A5 JP 2002522508A5 JP 2000564651 A JP2000564651 A JP 2000564651A JP 2000564651 A JP2000564651 A JP 2000564651A JP 2002522508 A5 JP2002522508 A5 JP 2002522508A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- tnf
- peptides
- amino acids
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 description 31
- 150000001413 amino acids Chemical class 0.000 description 18
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 12
- 238000000034 method Methods 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 6
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 5
- 235000018417 cysteine Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 102000057041 human TNF Human genes 0.000 description 4
- 108010021152 pepBs1-Ac peptide Proteins 0.000 description 4
- GJLXVWOMRRWCIB-MERZOTPQSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanamide Chemical compound C([C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=C(O)C=C1 GJLXVWOMRRWCIB-MERZOTPQSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98870180 | 1998-08-14 | ||
| EP98870180.1 | 1998-08-14 | ||
| EP98870198.3 | 1998-09-18 | ||
| EP98870198 | 1998-09-18 | ||
| EP98870222.1 | 1998-10-21 | ||
| EP98870222 | 1998-10-21 | ||
| PCT/EP1999/005806 WO2000009149A1 (en) | 1998-08-14 | 1999-08-10 | Tnf-derived peptides for use in treating oedema |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002522508A JP2002522508A (ja) | 2002-07-23 |
| JP2002522508A5 true JP2002522508A5 (enExample) | 2006-09-21 |
| JP4542266B2 JP4542266B2 (ja) | 2010-09-08 |
Family
ID=27239778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000564651A Expired - Lifetime JP4542266B2 (ja) | 1998-08-14 | 1999-08-10 | 浮腫の治療に使用されるｔｎｆ由来のペプチド |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030105021A1 (enExample) |
| EP (3) | EP1247531B1 (enExample) |
| JP (1) | JP4542266B2 (enExample) |
| CN (1) | CN1181886C (enExample) |
| AT (2) | ATE395072T1 (enExample) |
| AU (1) | AU764992B2 (enExample) |
| BR (1) | BR9912899A (enExample) |
| CA (1) | CA2334941C (enExample) |
| CZ (1) | CZ302862B6 (enExample) |
| DE (2) | DE69938743D1 (enExample) |
| DK (1) | DK1264599T3 (enExample) |
| ES (1) | ES2296872T3 (enExample) |
| HU (1) | HU227661B1 (enExample) |
| IL (2) | IL141064A0 (enExample) |
| NZ (1) | NZ509604A (enExample) |
| PL (1) | PL203706B1 (enExample) |
| PT (1) | PT1264599E (enExample) |
| TR (1) | TR200100338T2 (enExample) |
| WO (1) | WO2000009149A1 (enExample) |
| ZA (1) | ZA200100656B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ509604A (en) | 1998-08-14 | 2003-05-30 | Innogenetics N | TNF-derived peptides for use in treating oedema |
| EP1781323B1 (en) | 2004-08-06 | 2010-02-17 | Nycomed GmbH | Composition comprising a pulmonary surfactant and a tnf-derived peptide |
| EP2009023A1 (en) * | 2007-06-04 | 2008-12-31 | Rentschler Beteiligungs GmbH | Novel peptides and their use for the treatment of edema |
| AT506150B1 (de) | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Zyklisches und cystein-freies peptid |
| AT506151B1 (de) | 2007-12-12 | 2010-01-15 | Apeptico Forschung Und Entwick | Fusionsprotein |
| AT507953B1 (de) * | 2009-03-05 | 2011-02-15 | Apeptico Forschung & Entwicklung Gmbh | Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität |
| AT509267A1 (de) * | 2010-01-14 | 2011-07-15 | Apeptico Forschung & Entwicklung Gmbh | Organische verbindungen zur regulierung von vektoriellen ionenkanälen |
| DK2397151T3 (en) | 2010-06-21 | 2015-05-18 | Apeptico Forschung & Entwicklung Gmbh | The treatment of the vascular complications of diabetes |
| AT510585B1 (de) * | 2010-11-18 | 2012-05-15 | Apeptico Forschung & Entwicklung Gmbh | Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase |
| US11161881B2 (en) * | 2010-11-18 | 2021-11-02 | Apeptico Forschung Und Entwicklung Gmbh | Composition comprising a peptide and an inhibitor of viral neuraminidase |
| EP2679239A1 (de) * | 2012-06-28 | 2014-01-01 | Apeptico Forschung und Entwicklung GmbH | Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit |
| US12004506B2 (en) | 2013-04-23 | 2024-06-11 | Apeptico Forschung Und Entwicklung Gmbh | Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment |
| JP6335279B2 (ja) * | 2013-04-23 | 2018-05-30 | アペプティコ フオルシユング ウント アントウィクラング ゲーエムベーハー | 式ｘ１−ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ−ｘ２の環状ペプチドを含んでなる医薬組成物および体外肺処置のための使用 |
| JP6397984B2 (ja) | 2014-03-18 | 2018-09-26 | アペプティコ・フォルシュング・ウント・エントヴィックルング・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＡｐｅｐｔｉｃｏ Ｆｏｒｓｃｈｕｎｇ Ｕｎｄ Ｅｎｔｗｉｃｋｌｕｎｇ Ｇｍｂｈ | 乾燥粉末ペプチド医薬 |
| CN110613838A (zh) * | 2018-06-19 | 2019-12-27 | 姜石松 | 增强细胞通透性的多肽及其应用 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| EP4051307B1 (en) | 2020-05-08 | 2023-02-01 | APEPTICO Forschung und Entwicklung GmbH | Peptide for prevention or treatment of covid-19 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE384179C (de) * | 1921-04-07 | 1923-10-27 | Ludwig Weil Dr | Laufrad fuer Kreiselpumpen und -geblaese |
| DE3841759A1 (de) | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
| CA2155103A1 (en) * | 1993-02-03 | 1994-08-18 | Rudolph Lucas | Tnf-alpha muteins and a process for preparing them |
| NZ509604A (en) | 1998-08-14 | 2003-05-30 | Innogenetics N | TNF-derived peptides for use in treating oedema |
-
1999
- 1999-08-10 NZ NZ509604A patent/NZ509604A/en not_active IP Right Cessation
- 1999-08-10 EP EP02077274A patent/EP1247531B1/en not_active Expired - Lifetime
- 1999-08-10 IL IL14106499A patent/IL141064A0/xx unknown
- 1999-08-10 DK DK02077256T patent/DK1264599T3/da active
- 1999-08-10 EP EP02077256A patent/EP1264599B1/en not_active Expired - Lifetime
- 1999-08-10 DE DE69938743T patent/DE69938743D1/de not_active Expired - Lifetime
- 1999-08-10 CA CA2334941A patent/CA2334941C/en not_active Expired - Lifetime
- 1999-08-10 CN CNB998096555A patent/CN1181886C/zh not_active Expired - Lifetime
- 1999-08-10 AU AU56209/99A patent/AU764992B2/en not_active Ceased
- 1999-08-10 AT AT02077274T patent/ATE395072T1/de active
- 1999-08-10 JP JP2000564651A patent/JP4542266B2/ja not_active Expired - Lifetime
- 1999-08-10 BR BR9912899-3A patent/BR9912899A/pt active Search and Examination
- 1999-08-10 AT AT02077256T patent/ATE374039T1/de active
- 1999-08-10 EP EP99942835A patent/EP1105152A1/en not_active Withdrawn
- 1999-08-10 CZ CZ20010538A patent/CZ302862B6/cs not_active IP Right Cessation
- 1999-08-10 PT PT02077256T patent/PT1264599E/pt unknown
- 1999-08-10 WO PCT/EP1999/005806 patent/WO2000009149A1/en not_active Ceased
- 1999-08-10 HU HU0103117A patent/HU227661B1/hu not_active IP Right Cessation
- 1999-08-10 TR TR2001/00338T patent/TR200100338T2/xx unknown
- 1999-08-10 DE DE69937206T patent/DE69937206T2/de not_active Expired - Lifetime
- 1999-08-10 ES ES02077256T patent/ES2296872T3/es not_active Expired - Lifetime
- 1999-08-10 PL PL345997A patent/PL203706B1/pl unknown
-
2001
- 2001-01-23 ZA ZA2001/00656A patent/ZA200100656B/en unknown
- 2001-01-24 IL IL141064A patent/IL141064A/en not_active IP Right Cessation
- 2001-02-09 US US09/779,703 patent/US20030105021A1/en not_active Abandoned
-
2002
- 2002-06-06 US US10/162,553 patent/US7258861B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002522508A5 (enExample) | ||
| AU761652B2 (en) | New peptide compounds that are analogues of the glucagon-like peptide-1 (7-37), a process for their preparation and pharmaceutical compositions containing them | |
| EP0477885B1 (en) | Parathyroid hormone derivatives | |
| Gregory et al. | The primary structure of human urogastrone | |
| US6080398A (en) | Truncated gro and KC chemokines having enhanced bioactivity | |
| EP1197220A3 (en) | Therapeutic methods and compositions based on delta proteins and nucleic acids | |
| KR950701937A (ko) | 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체(glucagon-like peptide and insulinotropin derivatives) | |
| WO1989005824A1 (en) | Site-specific homogeneous modification of polypeptides to facilitate covalent linkages to a hydrophilic moiety | |
| EP0748817A2 (en) | Parathyroid hormone derivatives and their use | |
| GB2275683A (en) | Human tumour necrosis factor muteins | |
| HU196846B (en) | Process for producing biologically active derivatives of human gamma-interferon and pharmaceutical compositions comprising the same | |
| Gafvelin et al. | A proform of secretin with high secretin‐like bioactivity | |
| US6709649B1 (en) | RANTES derived peptides with anti-HIV activity | |
| US5039790A (en) | Bioactive fragment of interleukin-1-B that has antagonistic activity | |
| US5587457A (en) | Neutrophil stimulating peptides | |
| JPH0625288A (ja) | ペプチドまたはその塩 | |
| CA2150909A1 (en) | Clotting inhibitor made from protostomia saliva | |
| JPH09157294A (ja) | 副甲状腺ホルモン誘導体 | |
| NZ236311A (en) | Des (64,65) human proinsulin and its production by enzymatic treatment of proinsulin | |
| JPH06220090A (ja) | ポリペプチド | |
| CA2202496C (en) | Neurotrophic peptides of activity dependent neurotrophic factor | |
| CN101883784B (zh) | N-端修饰的干扰素-α | |
| AU7476291A (en) | Neutrophil stimulating peptides | |
| JP2003501109A5 (enExample) | ||
| RU2119800C1 (ru) | Аналог пептида фактора гормона роста (фгр), способ стимулирования секреции гормона роста и композиция для стимулирования секреции |